ARO, RMTI, PHOT & Extended Watchlist

Aeropostale, Inc. ARO

At the beginning of August, ARO began to experience a substantial sell-off that would cause the stock to fall from the $15-range to less than $8 at the beginning of this month. We are standing at the ready this morning as we’ve observed some northward pre-market trading, with shares changing hands for as much as 10.13. The significant gaps on the chart being filled could provide not only opportunities on the stock side of things, but in the trading of options contracts as well.

The 10/19 $9.00 Calls are of particular interest to us; Closing at .35 yesterday, and with this morning’s gap-up activity, these calls could open up as much as 100%  In that event, we would be looking for a consolidation before getting our feet wet.


Rockwell Medical, Inc. RMTI

RMTI would make a nice intraday move for us after its appearance in yesterday’s morning report, running from a low of 8.75 and reaching its peak at 11.80, good enough for a 35% gain.

Following the high, the stock came back as low as 9.85. Moving we are looking for the stock to hold support at its previous swing low of 8.75. In the meantime the company released an encouraging PR today announcing the completion of an important step in getting a new kidney drug to market, that appears to be contributing to yet another gap-up situation today.

WIXOM, MI–(Marketwired – Sep 17, 2013) – Rockwell Medical (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, today announced the U.S. Food & Drug Administration (FDA) accepted the proposed proprietary trade name Trifericfor the Company’s investigational iron-delivery drug, previously known as Soluble Ferric Pyrophosphate (SFP), which is intended for treating iron deficiency in chronic kidney disease patients receiving hemodialysis. A request for proprietary name review for Trifericwill be filed with the New Drug Application (NDA) submission.>>>FULL STORY


GroLife, Inc. PHOT

We had another gainer in PHOT yesterday, as the stock jumped from .046 to .061, affording us the opportunity at a 33% intraday rip. Since 08/30 when we re-mentioned PHOT, it has been as low as .0318, which makes yesterday’s high a move of 93%

For almost a year now, we’ve placed a strong focus on marijuana-related stocks, publishing several reports, and doing the most recent followup at the end of August. The industry has, and we believe, will continue to bring us profits in the future. It’s for that reason we suggest everyone keep a marijuana stock watchlist of their own. We have only just begun to realize the potential for this up-and-coming sector, which is certain to be a high-growth area for years to come.


Extended Watchlist:
AGEN, NBS, BCRX, RGDO, SUTR, DNDN, MATR, SD